Federal officials announced on Friday that health providers will be able to continue prescribing drugs for opioid addiction and ADHD over telehealth for another year, ending a lengthy debate among policymakers. The temporary rules issued by the Drug Enforcement Agency during the pandemic allowed providers to prescribe controlled substances such as buprenorphine and Adderall without an initial in-person meeting, and were set to expire on January 1. The extension until the end of 2025 comes after months of uncertainty and nearly 40,000 comments on proposed rules.
The pandemic flexibilities opened up discussions about the strict regulations that some believe hinder access to vital treatments. It also led to the rise of telehealth companies that offered care under the relaxed rules. However, in 2023, the DEA introduced draft rules to reinstate restrictions, which received backlash from telehealth advocates and providers. Last October, the agency extended the flexibilities until the end of this year, delaying the resolution of the ongoing debate.
The leaked draft rules included stringent restrictions, such as requiring half of a provider’s controlled substance prescriptions to be written for patients seen in person and mandating providers to check patients against prescription drug monitoring programs in all 50 states. Telehealth companies raised concerns that these regulations would be unsustainable and could lead to the closure of some services. Due to inter-agency conflicts and political reasons, the DEA did not meet its promise to issue final rules by the fall.
The temporary extension was seen as a response to concerns about companies overprescribing stimulants for profit, with recent arrests of leaders from an ADHD-focused telehealth company fueling these suspicions. While acknowledging the need for oversight to prevent fraudulent practices, telehealth companies stressed the importance of continuing progress in opioid addiction care. The extension specifically mentioned the urgent public health need for continued access to buprenorphine for opioid use disorder treatment.
Despite the celebration of the extension by proponents of buprenorphine access, many believe that it is still a temporary measure and insufficient in the long run. Stephanie Strong, CEO of telehealth addiction medicine company Boulder Care, emphasized that telehealth is not just a temporary solution but a crucial necessity. The extension of telehealth policies is just one of several expiring at the end of the year, with Congress considering legislation to extend rules allowing Medicare enrollees to receive a wide range of services over telehealth for two more years.
As the telehealth landscape continues to evolve, stakeholders are advocating for a balance between ensuring patient access to essential treatments and safeguarding against misuse and fraudulent practices. The extension of the telehealth prescription rules offers a temporary reprieve, but the need for long-term solutions and comprehensive policies remains a pressing concern.
